Unnamed Drug Candidate
Oncology
Preclinical/Early ClinicalPipeline Expansion
Key Facts
Indication
Oncology
Phase
Preclinical/Early Clinical
Status
Pipeline Expansion
Company
About Burning Rock Biotech
Burning Rock Biotech's mission is to 'Guard Life via Science' by becoming a new pillar in the international healthcare industry. The company has established itself as a leader in China's precision oncology diagnostics market, with a portfolio of CE-marked kits, a CLIA/CAP-certified lab, and a U.S. FDA Breakthrough Device designation. Its strategy is built on a dual business model of selling IVD products and providing LDT services, while strategically investing in R&D for early cancer detection and a nascent therapeutic pipeline to drive long-term growth.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |